Longterm safety, efficacy, and radiographic outcome with etanercept treatment in patients with early rheumatoid arthritis. - Wikidata - awgldk - TriplyDB

Longterm safety, efficacy, and radiographic outcome with etanercept treatment in patients with early rheumatoid arthritis.

Longterm safety, efficacy, and radiographic outcome with etanercept treatment in patients with early rheumatoid arthritis.

http://www.wikidata.org/entity/Q44003346

about

TNF inhibitor therapy for rheumatoid arthritis Humanized anti-interleukin-6-receptor antibody (tocilizumab) monotherapy is more effective in slowing radiographic progression in patients with rheumatoid arthritis at high baseline risk for structural damage evaluated with levels of biomarkers, rad Possible association of etanercept, venous thrombosis, and induction of antiphospholipid syndrome.Bone damage in rheumatoid arthritis: mechanistic insights and approaches to prevention Tumor necrosis factor inhibitor-associated dermatomyositis Early combination disease-modifying antirheumatic drug therapy and tight disease control improve long-term radiologic outcome in patients with early rheumatoid arthritis: the 11-year results of the Finnish Rheumatoid Arthritis Combination Therapy tr Generalized bone loss as a predictor of three-year radiographic damage in African American patients with recent-onset rheumatoid arthritis.Continued inhibition of structural damage over 2 years in patients with rheumatoid arthritis treated with rituximab in combination with methotrexate.Efficacy, tolerability and safety of biologic therapy in rheumatoid disease: patient considerations.Development of EULAR recommendations for the reporting of clinical trial extension studies in rheumatology.Four-year follow-up of infliximab therapy in rheumatoid arthritis patients with long-standing refractory disease: attrition and long-term evolution of disease activity.Safety analyses of adalimumab (HUMIRA) in global clinical trials and US postmarketing surveillance of patients with rheumatoid arthritis.A long-term, open-label trial of the safety and efficacy of etanercept (Enbrel) in patients with rheumatoid arthritis not treated with other disease-modifying antirheumatic drugs High IgA rheumatoid factor levels are associated with poor clinical response to tumour necrosis factor alpha inhibitors in rheumatoid arthritis Adalimumab alone and in combination with disease-modifying antirheumatic drugs for the treatment of rheumatoid arthritis in clinical practice: the Research in Active Rheumatoid Arthritis (ReAct) trial.Guidelines for the proper use of etanercept in Japan.An open-label pilot study of the effectiveness of adalimumab in patients with rheumatoid arthritis and previous infliximab treatment: relationship to reasons for failure and anti-infliximab antibody status.Immune-mediated inflammatory diseases (IMIDs) and biologic therapy: a medical revolution Level of radiographic damage and radiographic progression are determinants of physical function: a longitudinal analysis of the TEMPO trial Tocilizumab in early progressive rheumatoid arthritis: FUNCTION, a randomised controlled trial.Long-term safety of rituximab in rheumatoid arthritis: 9.5-year follow-up of the global clinical trial programme with a focus on adverse events of interest in RA patients.Etanercept Promotes Bone Formation via Suppression of Dickkopf-1 Expression in Rats with Collagen-Induced Arthritis.Update on the use of etanercept across a spectrum of rheumatoid disorders.Long-term safety and efficacy of tocilizumab, an anti-IL-6 receptor monoclonal antibody, in monotherapy, in patients with rheumatoid arthritis (the STREAM study): evidence of safety and efficacy in a 5-year extension study.The clinical efficacy and safety of certolizumab pegol (CZP) in the treatment of rheumatoid arthritis: focus on long-term use, patient considerations and the impact on quality of life Incidences of serious infections and tuberculosis among patients receiving anti-tumor necrosis factor-α therapy.Efficacy and Safety of Subcutaneous Golimumab in Methotrexate-Naive Patients With Rheumatoid Arthritis: Five-Year Results of a Randomized Clinical Trial.A survey of inclusion of the time element when reporting adverse effects in randomised controlled trials of cyclo-oxygenase-2 and tumour necrosis factor alpha inhibitors Blocking of tumor necrosis factor activity promotes natural repair of osteochondral defects in rabbit knee.Transcriptional profiling of leukocytes from rheumatoid arthritis patients before and after anti-tumor necrosis factor therapy: A comparison of anti-nuclear antibody positive and negative subsets.Rheumatoid arthritis: pathological mechanisms and modern pharmacologic therapies.

P2860

Q28972424-E88E715F-E8F7-4372-9870-EEEA06542333 Q33614786-1C993F90-32B8-46D2-9E1E-67B02F5F54F5 Q33737258-AC6CDD27-DA84-4C87-B008-045D27111CE0 Q34001621-803476C9-889C-40DB-840A-54422A1B113A Q34015824-54D82699-CCEF-44B5-991E-73C355F0B6B5 Q34027654-38383EB9-D667-4B5B-910E-D6D401AD24BF Q34067290-AF921B02-BBD0-45CE-9E63-9378062ABB3F Q34110049-85B1296E-A69C-48E8-8676-1FED166790D2 Q35026464-A763EB2A-80FE-46EE-98E9-03F57496A212 Q35605474-6C785C35-99D7-44BC-9994-83E989395BB3 Q35605643-D8F58E3B-0B8C-4932-AA43-9CBA03835F55 Q35637322-FA14C042-D671-40E8-AE26-1ABFBA3E1F6E Q35638528-86E604C6-FD5C-4C81-B76B-A83797359B6B Q35760039-73414F1C-F1D5-45BE-B437-946E62998708 Q35953319-90DF40DA-8FBD-40B7-8AAB-24F6CAC892F5 Q36457930-BE19BB2E-7EC6-4868-A868-686CEE3B4859 Q36772881-631FBB8D-4A9A-4391-9769-C52087A71A8B Q36778450-F1387B91-E686-4156-B457-32079CD32947 Q36946654-7C79DC76-D223-41BC-B30C-D85C3B6A52FE Q36968747-3474AE72-3034-406E-AE46-C724D80069FC Q37130018-0AF45779-005B-4D3F-8488-0A87473ED936 Q37140765-DF8B14CB-F7BD-409E-AD01-DDE88E944969 Q37290628-43DC5F5A-0721-45FF-91D0-654CD8FA509E Q37321296-B50DCB04-5FFF-4F71-8E54-92FC5F8303A5 Q37358093-3CACC660-EFAB-4725-92FA-72331A35F16F Q37606758-DCCA8770-2033-4784-AF1F-B9F0601C9526 Q40948833-BA032B94-55B7-4E4A-B1E7-605854095FC9 Q41876223-5BA02B25-AF57-4CED-A6FC-324D3B99CB1C Q42004548-F66F33A8-2C5D-46E1-8FC5-99CEDAA08C9C Q42247134-1CC7298A-AB40-46B0-B9C6-AD821A5BD901 Q55025616-87D9AACD-E617-49B7-99D0-A6147963E760

P2860

Longterm safety, efficacy, and radiographic outcome with etanercept treatment in patients with early rheumatoid arthritis.

http://www.wikidata.org/entity/Q44003346

description

2005 nî lūn-bûn

@nan

2005年の論文

@ja

2005年学术文章

@wuu

2005年学术文章

@zh

2005年学术文章

@zh-cn

2005年学术文章

@zh-hans

2005年学术文章

@zh-my

2005年学术文章

@zh-sg

2005年學術文章

@yue

2005年學術文章

@zh-hant

name

Longterm safety, efficacy, and ...... th early rheumatoid arthritis.

@en

Longterm safety, efficacy, and ...... th early rheumatoid arthritis.

@nl

type

label

Longterm safety, efficacy, and ...... th early rheumatoid arthritis.

@en

Longterm safety, efficacy, and ...... th early rheumatoid arthritis.

@nl

prefLabel

Longterm safety, efficacy, and ...... th early rheumatoid arthritis.

@en

Longterm safety, efficacy, and ...... th early rheumatoid arthritis.

@nl

P1433

Q44003346-740DC8D4-497F-4762-BDAA-DF9C9911C2CF

P1476

Q44003346-37ACF48B-2FD0-4DD6-BBC0-E21E5FD428B5

P2093

Q44003346-04C5CC9B-5586-4C81-8D07-EEE35F233219

Q44003346-0B9F1F3E-21E3-478A-9035-E849B521CA3B

Q44003346-3A1B4246-2EEC-447D-8FA1-603A79D0923E

Q44003346-C4301FB5-63C6-4C32-94F8-C55B5FD5C21C

Q44003346-C6C0CD09-603E-4C37-9A87-047F15811DBB

Q44003346-DD912660-D3F6-42E5-945C-384FB584D19A

Q44003346-DFF2B44A-1AE2-4225-8600-C4CC4CA27589

Q44003346-FC6D2FE6-6C64-4097-BE2A-4B42B75E047F

P304

Q44003346-BFF0DA0D-2CDD-41F5-8D5D-EA6750D8C328

P31

Q44003346-4B5C1450-CED3-412C-8729-59593B462C76

P407

Q44003346-178F8E9A-A68D-4E2F-9A34-E91835AEEE41

P433

Q44003346-6021AD70-A6C0-4289-8214-5784F79D67D0

P478

Q44003346-28A8B8FC-C431-4EA5-989B-FC82846FBF8B

P577

Q44003346-3846AEA4-26BF-4905-BD81-D6B11C2525B0

P698

Q44003346-8BA664A4-B419-4A4C-9C4F-0C6E4D9B4F89

P1433

The Journal of Rheumatology

P1476

Longterm safety, efficacy, and ...... th early rheumatoid arthritis.

@en

P2093

James B Whitmore

http://www.w3.org/2001/XMLSchema#string

Joan M Bathon

http://www.w3.org/2001/XMLSchema#string

Jonathan A Leff

http://www.w3.org/2001/XMLSchema#string

Larry W Moreland

http://www.w3.org/2001/XMLSchema#string

Mark C Genovese

http://www.w3.org/2001/XMLSchema#string

Richard W Martin

http://www.w3.org/2001/XMLSchema#string

Roy M Fleischmann

http://www.w3.org/2001/XMLSchema#string

Wayne H Tsuji

http://www.w3.org/2001/XMLSchema#string

P304

1232-1242

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P407

P433

7

http://www.w3.org/2001/XMLSchema#string

P478

32

http://www.w3.org/2001/XMLSchema#string

P577

2005-07-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

15996057

http://www.w3.org/2001/XMLSchema#string